Metrics of uterine myomatosis symptomatology in clinical practice

Czech version

Authors: R. Hudeček; L. Mekiňová; S. Šimová; L. Bánovská; A. Hledíková
Authors‘ workplace: Gynekologicko-porodnická klinika LF MU a FN Brno
Published in: Ceska Gynekol 2024; 89(2): 144-150
Category:
doi: https://doi.org/10.48095/cccg2024144

Overview

Aim: A review of diagnostic options and standardized methods for specifying clinical symptoms associated with uterine myomatosis. Methods: A literature search of databases aimed at finding validated metrics for assessing myomas symptomatology. Results: Summary of obligatory and optional examination methods in the diagnosis of uterine fibroids and methods of examination of reproductive parameters of the couple in relation to myomatosis. Defining the metrics of bleeding manifestations of myomatosis with emphasis on the “Pictorial Bleeding Assessment Chart”. Reviewing metrics of algic manifestations of myomatosis and quality of life with emphasis on the “Quality of Life Questionnaire – Myomatosis – Severity Symptom Scale”. Conclusion: The purpose of the applicable metrics, which summarize objective findings and subjective complaints of patients, is to describe and evaluate possible correlations and dynamics of changes in the health status, depending on the chosen therapy.

Keywords:

uterine fibroid symptoms

Sources

1. Výbor ČGPS ČLS JEP: Diagnostika a léčba děložních myomů. Sbírka doporučených postupů ČGPS ČLS JEP č. 5/2021. 2021 [online]. Dostupné z: https: //www.gynultrazvuk.cz/uploads/recommendedaction/97/doc/j-2021-05-diagnostika-a-lecba-deloznich-myomu.pdf.

2. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update Nov 2016; 22 (6): 665–686. doi: 10.1093/humupd/dmw023.

3. Van Den Bosch T, Dueholm M, Leone FP et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol 2015; 46 (3): 284–298. doi: 10.1002/uog.14806.

4. Munro MG, Critchley HO, Fraser IS. FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011; 95 (7): 2204–2208, 2208.e1–e3. doi: 10.1016/j.fertnstert.2011.03.079.

5. Graziano A, Lo Monte G, Soave I et al. Sonohysterosalpingography: a suitable choice in infertility workup. J Med Ultrason 2013; 40 (3): 225–229. doi: 10.1007/s10396-012-0417-0.

6. Filipinská E, Hudeček R, Mekiňová L et al. Vliv myomektomie na morfologii děložního a tubárního faktoru infertility. Ceska Gynekol 2018; 83 (6): 412–417.

7. Kadlecová J, Hudeček R, Mekiňová L et al. Histologické typy děložních myomů u pacientek v reprodukčním věku a postmenopauze. Ceska Gynekol 2015; 80 (5): 360–364.

8. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicans need to know. Obstet Gynecol 2006; 107 (4): 917–921. doi: 10.1097/01.AOG.0000206161.849- 65.0b.

9. Faerstein E, Szklo M, Rosenhaim N. Risk factor for uterine leiomyomata: a practice-based case-control study. I. African-American heritage, reproductive history, body size and smoking. Am J Epidemiol 2001; 153 (1): 1–10. doi: 10.1093/aje/153.1.1.

10. Crha K, Ješeta M, Pilka R et al. Adenomyóza – možný vliv na funkci a receptivitu endometria. Ceska Gynekol 2021; 86 (3): 205–209. doi: 10.48095/cccg2021205.

11. Mekiňová L, Janků P, Filipinská E et al. Incidence císařského řezu a úspěšnost vaginálně vedeného porodu u těhotných po myomektomii. Ceska Gynekol 2016; 81 (6): 404–410.

12. Andonovová V, Hruban L, Gerychová R et al. Ruptura dělohy v těhotenství a při porodu: rizikové faktory, příznaky a perinatální výsledky – retrospektivní analýza. Ceska Gynekol 2019; 84 (2): 121–128.

13. Donnez J, Hudeček R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103 (2): 519.e3–527.e3. doi: 10.1016/j.fertnstert.2024. 10.038.

14. Marsh EE, Al-Hendy A, Kappus D et al. Prevalence and treatment of uterine fibroids: a survey of U.S. women. J Womens Health (Larchmt) 2018; 27 (11): 1359–1367. doi: 10.1089/jwh.2018. 7076.

15. Munro MG, Balen AH, Cho SH et al. The FIGO ovulatory disorders classification system. Int J Gynecol Obstet 2022; 159 (1): 1–20. doi: 10.1002/ijgo.14331.

16. Munro MG, Critchley HO, Fraser IS et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet 2018; 143 (3): 393–408. doi: 10.1002/ijgo. 12666.

17. James AH. Heavy menstrual bleeding: work-up and management. Hematology Am Soc Hematol Educ Program 2016; 2016 (1): 236–242. doi: 10.1182/asheducation-2016.1.236.

18. Haefeli M, Elfering A. Pain assessment. Eur Spine J 2006; 15 (Suppl 1): S17–S24. doi: 10.1007/s00586-005-1044-x.

19. Donnez J, Donnez O, Matule D et al. Longterm medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016; 105 (1): 165.e4–173.e4. doi: 10.1016/j.fertnstert.2015. 09.032.

20. Keizer AL, Van Kesteren PJM, Terwee C et al. Uterine Fibroid Symptom and Quality of Life questionnaire (UFS-QOL NL) in the Dutch population: a validation study. BMJ Open Nov 2021; 11 (11): e052664. doi: 10.1136/bmj open-2021-052664.

21. Tsuzuki Y, Tsuzuki S, Wada S et al. Recovery of quality of life after laparoscopic myomectomy. J Obstet Gynaecol Res 2019; 45 (1): 176–181. doi: 10.1111/jog.13808.

22. Tung SL, Chou TY, Tseng HS et al. A retrospective study of magnetic resonance – guided focused ultrasound ablation for uterine myoma Taiwan. Taiwan J Obstet Gynecol 2016; 55 (2): 646–649. doi: 10.1016/j.tjog.2015. 03.011.

ORCID autorů

R. Hudeček 0000-0003-0617-0126

L. Mekiňová 0000-0002-1839-2802

S. Šimová 0009-0005-0058-2252

L. Bánovská 0000-0002-7501-877X

A. Hledíková 0009-0004-2441-5224

Doručeno/Submitted: 21. 9. 2023

Přijato/Accepted: 20. 10. 2023

MUDr. Lenka Mekiňová

Gynekologicko-porodnická klinika

LF MU a FN Brno

Obilní trh 11